GSK-49653/292



A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Three Dose Levels of Rosiglitazone Maleate in the Treatment of Moderate to Severe Plaque Psoriasis.
rosiglitazone
49653/292
Psoriasis
Phase 2
 
An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
January 2014